Plain-English translation of NCT06331988 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying the role of gut bacteria (called the microbiome) in colorectal cancer development and how well standard treatments work. Researchers want to understand why some patients do well after surgery and chemotherapy while others have their cancer return, and whether analyzing a patient's gut bacteria could help predict treatment success.
Even with the best surgery and chemotherapy available, about 30–50% of colorectal cancer patients still experience cancer returning after treatment. Current methods of predicting who will benefit most from chemotherapy don't always work well, so researchers believe studying gut bacteria may reveal new insights into why some patients respond better than others to treatment.
You likely qualify if…
You likely don't qualify if…
You would have surgery to remove the colorectal cancer as your standard treatment, followed by chemotherapy if recommended by your doctor. During this process, researchers would collect samples (blood, tissue, or stool) before surgery, during treatment, and after treatment to study your gut bacteria and immune response. You would need to attend scheduled visits and follow all study procedures while receiving your regular cancer care at the European Institute of Oncology.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Italy